Pieter Gillard

6.0k total citations · 2 hit papers
101 papers, 2.3k citations indexed

About

Pieter Gillard is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Genetics. According to data from OpenAlex, Pieter Gillard has authored 101 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Surgery, 67 papers in Endocrinology, Diabetes and Metabolism and 57 papers in Genetics. Recurrent topics in Pieter Gillard's work include Pancreatic function and diabetes (66 papers), Diabetes Management and Research (62 papers) and Diabetes and associated disorders (54 papers). Pieter Gillard is often cited by papers focused on Pancreatic function and diabetes (66 papers), Diabetes Management and Research (62 papers) and Diabetes and associated disorders (54 papers). Pieter Gillard collaborates with scholars based in Belgium, United States and Netherlands. Pieter Gillard's co-authors include Chantal Mathieu, Bart Keymeulen, Daniël Pipeleers, Sara Charleer, Christophe De Block, Frank Nobels, Katrien Benhalima, Frans Gorus, Steffen Fieuws and Robert Hilbrands and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Pieter Gillard

98 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

2024 74 citations Johannes F.E. Mann, Peter Rossing et al. Nature Medicine profile →
Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial

2024 55 citations Katrien Benhalima, Dominique Ballaux et al. profile →

Peers

Countries citing papers authored by Pieter Gillard

Since Specialization

Citations

This map shows the geographic impact of Pieter Gillard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pieter Gillard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pieter Gillard more than expected).

Fields of papers citing papers by Pieter Gillard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pieter Gillard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pieter Gillard. The network helps show where Pieter Gillard may publish in the future.

Co-authorship network of co-authors of Pieter Gillard

This figure shows the co-authorship network connecting the top 25 collaborators of Pieter Gillard. A scholar is included among the top collaborators of Pieter Gillard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pieter Gillard. Pieter Gillard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial 2025 ·EClinicalMedicine ·(unknown), (unknown), (unknown), Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, (unknown), Frank Nobels, Liesbeth Van Huffel, (unknown), Dahae Lee, (unknown), Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter, Annouschka Laenen, Pieter Gillard, Chantal Mathieu, Jeroen Luyten, Katrien Benhalima	2
2	Real-World Glycemic and Person-Reported Outcomes After Tandem Control-IQ Initiation in Children With Type 1 Diabetes 2025 ·The Journal of Clinical Endocrinology & Metabolism ·(unknown), (unknown), Guy Massa, Inge Gies, (unknown), (unknown), (unknown), Marieke den Brinker, (unknown), (unknown), Marie-Christine Lebrethon, (unknown), Philippe A. Lysy, L Dooms, Chantal Mathieu, Kristina Casteels, Pieter Gillard	2
3	Repeated OGTT Versus Continuous Glucose Monitoring for Predicting Development of Stage 3 Type 1 Diabetes: A Longitudinal Analysis 2025 ·Diabetes Care ·(unknown), Bart Keymeulen, Ursule Van de Velde, (unknown), Bruno Lapauw, Christophe De Block, Pieter Gillard, (unknown), Eric V. Balti, (unknown), Willem Staels, (unknown), Marieke den Brinker, (unknown), (unknown), (unknown), Frans Gorus	5
4	Review Article – Diabetes Technology in the Hospital: An Update 2024 ·Current Diabetes Reports ·(unknown), Roman Vangoitsenhoven, Pieter Gillard, Chantal Mathieu	2
5	Health‐related quality of life of people with type 1 diabetes: An IMI2 SOPHIA post hoc analysis of FUTURE and ADJUNCT ‐ ONE 2024 ·Diabetes Obesity and Metabolism ·Nele Steenackers, Thomas Sparsø, Sara Charleer, Christophe De Block, Diederik De Cock, (unknown), Chantal Mathieu, Frank Nobels, Sofia Pazmiño, Jonathan Rosen, Carmen Hurtado del Pozo, Pieter Gillard, Bart Van der Schueren	0
6	The Health Economics of Automated Insulin Delivery Systems and the Potential Use of Time in Range in Diabetes Modeling: A Narrative Review 2024 ·Diabetes Technology & Therapeutics ·Chantal Mathieu, (unknown), Pieter Gillard, Ohad Cohen, Robert A. Vigersky, Simona de Portu, (unknown)	3
7	LONG-TERM PROPHYLACTIC TREATMENT PREFERENCES OF PATIENTS WITH HEREDITARY ANGIOEDEMA 2024 ·Annals of Allergy Asthma & Immunology ·(unknown), (unknown), C. Olson, Thomas L. Ray, Lorena López-González, Pieter Gillard, Sandra Nestler-Parr, Christine Poulos, Marco Lionetti	1
8	Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial breakdown → 2024 ·Nature Medicine ·Johannes F.E. Mann, Peter Rossing, George L. Bakris, (unknown), Heidrun Bosch‐Traberg, Robert S. Busch, David M. Charytan, Samy Hadjadj, Pieter Gillard, José Luis Górriz, Thomas Idorn, Linong Ji, Kenneth W. Mahaffey, Vlado Perkovic, Søren Rasmussen, Roland E. Schmieder, Richard E. Pratley, Katherine R. Tuttle	74
9	SARS‐CoV‐2 vaccine antibody response and breakthrough infections in transplant recipients 2023 ·Journal of Medical Virology ·(unknown), (unknown), Kris Bogaerts, Pieter Vermeersch, Katrien Lagrou, Geert Molenberghs, Filip Rega, Laurens J. Ceulemans, Dirk Van Raemdonck, Ina Jochmans, Diethard Monbaliu, Jacques Pirenne, Tim Vanuytsel, Pieter Gillard, Hélène Schoemans, Johan Van Cleemput, Dirk Kuypers, Robin Vos, Frederik Nevens, Jef Verbeek	10
10	Hypoglycaemia after Initiation of CFTR Modulator Therapy in a Cystic Fibrosis Patient without Diabetes 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Lieven Dupont, Natalie Lorent, Pascal Van Bleyenbergh, Pieter Gillard, Bart Van der Schueren, Ann Mertens, Chantal Mathieu, Roman Vangoitsenhoven	0
11	Sustained Impact of Intermittently Scanned Continuous Glucose Monitoring on Treatment Satisfaction and Severe Hypoglycemia in Adults with Type 1 Diabetes (FUTURE): An Analysis in People with Normal and Impaired Awareness of Hypoglycemia 2023 ·Diabetes Technology & Therapeutics ·Sara Charleer, Christophe De Block, (unknown), Liesbeth Van Huffel, Frank Nobels, Chantal Mathieu, Pieter Gillard	7
12	Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2 , in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial 2022 ·Diabetes Obesity and Metabolism ·Lorenzo Piemonti, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose, Paolo Pozzilli, Francesco Giorgino, Efisio Cossu, L. Daffonchio, (unknown), Pier Adelchi Ruffini, Anna Rita Maurizi, (unknown), Marcello Allegretti	36
13	Diabetic Ketoacidosis After Sodium–Glucose Cotransporter Inhibitor Initiation Under Advanced Hybrid Closed-Loop Therapy in Type 1 Diabetes 2022 ·Diabetes Technology & Therapeutics ·(unknown), Chantal Mathieu, Pieter Gillard	4
14	Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients 2021 ·American Journal of Transplantation ·(unknown), (unknown), Robert Hilbrands, Ursule Van de Velde, (unknown), Geert Stangé, (unknown), (unknown), Zhidong Ling, Bart O. Roep, Pieter Gillard, Daniël Pipeleers, Bart Keymeulen, Daniel Jacobs‐Tulleneers‐Thevissen	9
15	Quality of life versus glycaemic variability and time in range in people with type 1 diabetes : sub study of the RESCUE-trial 2020 ·Ghent University Academic Bibliography (Ghent University) ·Pieter Gillard, (unknown), (unknown), Sara Charleer, (unknown), Kristien J. Ledeganck, Bart Keymeulen, Laurent Crenier, Régis Radermecker, Bruno Lapauw, Chris Vercammen, Frank Nobels, Chantal Mathieu, Christophe De Block	1
16	A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes 2020 ·Diabetologia ·Bart Keymeulen, André van Maurik, David R. Inman, (unknown), René McLaughlin, Rachel Gittelman, Bart O. Roep, Pieter Gillard, Robert Hilbrands, Frans Gorus, Chantal Mathieu, Ursule Van de Velde, Nicolas Wisniacki, Antonella Napolitano	38
17	Formation of amyloid in encapsulated human pancreatic and human stem cell-generated beta cell implants 2020 ·American Journal of Transplantation ·(unknown), (unknown), Geert Stangé, (unknown), (unknown), (unknown), Zhidong Ling, Robert Hilbrands, Pieter Gillard, Bart Keymeulen, Evert Kroon, Gunilla T. Westermark, Daniel Jacobs‐Tulleneers‐Thevissen, Daniël Pipeleers	3
18	Combined Analysis of GAD65, miR-375, and Unmethylated Insulin DNA Following Islet Transplantation in Patients With T1D 2018 ·The Journal of Clinical Endocrinology & Metabolism ·Sarah Roels, (unknown), Sarah A. Tersey, Geert Stangé, Dieter De Smet, Eric V. Balti, Pieter Gillard, Bart Keymeulen, Zhidong Ling, Daniël Pipeleers, Frans Gorus, Raghavendra G. Mirmira, Geert A. Martens	11
19	Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study 2015 ·The Journal of Clinical Endocrinology & Metabolism ·Marc Claesen, Pieter Gillard, Frank De Smet, (unknown), Bart De Moor, Chantal Mathieu	20
20	OnabotulinumtoxinA improves spasticity related pain in post-stroke patients: Findings from a randomized controlled trial 2014 ·Annals of Physical and Rehabilitation Medicine ·J. Wissel, (unknown), Yuewen Ma, Anthony B. Ward, Jörgen Borg, Per Ertzgaard, (unknown), Pieter Gillard	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact